MiMedx Group stock shifts toward surgery as Sanara deal awaits FTC
Published on 11/12/2026 at 04:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMiMedx advances its surgical strategy
- Management presented surgery as MiMedx's main growth engine at the Canaccord Genuity forum on November 11.
- The planned Sanara MedTech acquisition remains subject to review by the Federal Trade Commission.
- Medicare reimbursement changes continue to weigh on the wound care business, while management expects greater stability in 2027.
MiMedx said on Wednesday, November 11, that its business is shifting further toward surgery as the wound care franchise continues to face pressure from Medicare reimbursement changes. The comments were made at Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum and reported by Investing.com.
MiMedx said its surgical franchise generated 40 million US dollars of third-quarter revenue and grew 9 percent in dollars year over year. Surgical products now account for about two-thirds of revenue, while management also reported positive adjusted EBITDA and free cash flow in the quarter.
Sanara transaction awaits FTC review
The proposed acquisition of Sanara MedTech remains the key strategic next step. MiMedx said all required approvals had been obtained except for clearance from the Federal Trade Commission and that the company was working with the agency through its Second Request process.
Management expects the combined company to generate roughly 400 million US dollars of first-year revenue with adjusted EBITDA margins above 20 percent. The transaction would also expand MiMedx's exposure to operating-room products, including no-rinse irrigation and bone fixation technologies.
Wound care faces reimbursement pressure
Medicare reimbursement reforms that took effect on January 1, 2026, have weighed on MiMedx's mature wound care business. Management said the 2027 physician fee schedule and outpatient payment rules leave the 2026 changes in place, but described the policy outlook as more stable.
MDXG traded at 3.32 US dollars in after-hours trading on Wednesday, November 11, at 4:00 p.m. Eastern time. The broader US equity market remains the relevant backdrop for investors following the company through the S&P 500.
MiMedx serves wound and surgical care
MiMedx develops regenerative medicine products for wound care, burn treatment and surgical applications. Its portfolio is based on human placental and other tissue technologies, with the company focused on helping clinicians manage chronic and hard-to-heal wounds as well as surgical recovery. MiMedx is headquartered in Marietta, Georgia, and is expanding its surgical footprint while maintaining its established wound care business.
MiMedx Group market facts
- Company: MiMedx Group, Inc.
- Ticker: MDXG
- Trading venue: Nasdaq
- Quote: 3.32 US dollars in after-hours trading on Wednesday, November 11, 2026, at 4:00 p.m. Eastern time
- Market capitalization: 484,472,975 US dollars at the quote timestamp
- Business: Regenerative medicine products for wound care, burn treatment and surgery
